96 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22756 | Male proven invasive breast cancer | Lissandra Dal Lago | Breast | EORTC | EORTC 10085p MALE BREAST | Trial closed for recruitment | EORTC 10085p MALE BREAST Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG, TBCRC and NABCG intergroup study | lissandra.dallago@hubruxelles.be | |||
| 22692 | any line / Lung metastasis | Konstantinos Stathopoulos | Lung | EORTC | EORTC 1658 | Trial closed | Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) | konstantinos.stathopoulos@hubruxelles.be | |||
| 22812 | Availability for long term follow up. Clinically node-negative | Catherine Philippson | Breast | EORTC | EORTC 22085 | Trial open for recruitment | A randomised phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast | accueil.cons.radiotherapie@hubruxelles.be | |||
| 29409 | Andrea Gombos | Breast | Novartis | EPIK-B5 | Trial open for recruitment | EPIK-B5: A Phase III, randomized, double-blind, placebocontrolled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HRpositive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor | accueil.oncologie@hubruxelles.be | 3 | 3 | ||
| 22798 | Relasped/refractory patient | Christiane Jungels | Multiple | Imcheck | EVICTION | Trial open for recruitment | A fist-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an Immune Checkpoint Inhibitor, in patients with advanced-stage, relapsed/refractory cancer | christiane.jungels@hubruxelles.be | 1 | 1 | |
| 22682 | Any line/ ER positive/ HER2 negative/ RECIST 1.1 | Philippe Aftimos | Breast | G1 Therapeutics | G1T48-01 | Trial closed | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination with Palbociclib in Women with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer (G1T48-01) | philippe.aftimos@hubruxelles.be | 1 | 1 | |
| 22764 | any line | Ahmad Hussein Awada | Multiple | Genentech-Roche | GO29674 | Trial closed | A Phase Ib, Open-Label, Dose-escalation Study of the safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients with Locally Advanced or Metastatic Solid Tumors | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 28537 | Triple negative | Ahmad Hussein Awada | Breast | Erytech | GRASPA-TNBC-2018-02 | Trial closed | A Randomized Phase 2/3 Study of Eryaspase in Combination with Gemcitabine and Carboplatin Chemotherapy versus Chemotherapy Alone As First-Line Treatment in Patients with Metastatic or Locally Recurrent Triple-Negative Breast Cancer | ahmad.awada@hubruxelles.be | 2/3 | 2 | |
| 28578 | Andrea Gombos | Breast | Seagen | HER2CLIMB-02 | Trial closed for recruitment | Randomized, double-blind, Phase III Trial of tucatinib or Placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02) | accueil.oncologie@hubruxelles.be | 3 | 3 | ||
| 22754 | Brain metastasis | Ahmad Hussein Awada | Multiple | Lilly | I3Y-MC-JPBO | Trial closed | A phase II study of Abemaciclib in patients with brain metastases secondary to hormone receptor positive breast cancer, non-small cell lung cancer, or melanoma | ahmad.awada@hubruxelles.be | 2 | 2 | |
| 22625 | RECIST 1.1, after standard trerapy | Ahmad Hussein Awada | Multiple | Lilly | I7W-MC-JQBA | Trial closed | A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22733 | ER+/HER2-. Metastatic | Andrea Gombos | Breast | Oslo University Hospital | ICON | Trial closed | A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer | accueil.oncologie@hubruxelles.be | 2 | 2 | |
| 22846 | Non-metastatic breast cancer/At the end of active treatment | Isabelle Merckaert | Breast | IJB_2484 | Trial closed | Impact of attentional bias towards threat on fear of cancer recurrence in breast cancer survivor | isabelle.merckaert@hubruxelles.be | ||||
| 22847 | Women treated for a non-metastatic breast cancer. At the end of active treatment (i.e. surgery, chemotherapy, radiotherapy). Experiencing moderate to high emotion dysregulation | Isabelle Merckaert | Breast | Institut Jules Bordet | IJB_2600 | Trial open for recruitment | Improving emotion regulation at the end of cancer treatment : A randomized controlled study assessing the impact of a multi-component psychological group intervention | isabelle.merckaert@hubruxelles.be |